ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

CYCN Cyclerion Therapeutics Inc

2.7501
-0.2099 (-7.09%)
After Hours
Last Updated: 16:00:23
Delayed by 15 minutes

Period:

Draw Mode:

Volume 625
Bid Price 1.16
Ask Price 3.00
News -
Day High 2.96

Low
1.7501

52 Week Range

High
5.25

Day Low 2.75
Company Name Stock Ticker Symbol Market Type
Cyclerion Therapeutics Inc CYCN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.2099 -7.09% 2.7501 16:00:23
Open Price Low Price High Price Close Price Prev Close
2.96 2.75 2.96 2.7501 2.96
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
12 625 $ 2.75 $ 1,719 - 1.7501 - 5.25
Last Trade Time Type Quantity Stock Price Currency
16:00:00 150 $ 2.7501 USD

Cyclerion Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
7.45M 2.71M - 0 -5.26M -1.94 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Cyclerion Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CYCN Message Board. Create One! See More Posts on CYCN Message Board See More Message Board Posts

Historical CYCN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.712.982.602.746600.04011.48%
1 Month3.063.19992.602.86824-0.3099-10.13%
3 Months3.003.982.603.122,101-0.2499-8.33%
6 Months1.915.251.75013.374,8320.840143.98%
1 Year4.185.251.75013.596,776-1.43-34.21%
3 Years65.0097.201.750146.68254,380-62.25-95.77%
5 Years303.80306.801.750164.62342,504-301.05-99.09%

Cyclerion Therapeutics Description

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.